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Osteogenesis by the bone marrow stromal stem cells (BMSSCs)
supports continuous bone formation and the homeostasis of the
bone marrowmicroenvironment. The mechanism that controls the
proliferation anddifferentiation of BMSSCs is not fully understood.
Here, we report that CD18, a surface protein present primarily on
hematopoietic cells, but not on differentiated mesenchymal cells,
is expressed by the stromal stem cells and plays a critical role in the
osteogenic process. Constitutive expression of CD18 on BMSSCs
using a retroviral promoter significantly enhances bone formation
in vivo, whereas genetic inactivation of CD18 in mice leads to
defective osteogenesis due to decreased expression of the osteo-
genic master regulator Runx2"Cbfa1. The defective osteogenesis
of the CD18-null BMSSCs can be restored by expressing full-length,
but not cytoplasmic domain-truncated, CD18. Radiographic anal-
yses with dual-energy x-ray absorptiometry and 3D microcom-
puted tomography show that mice lacking CD18 have decreased
bone mineral density and exhibit certain features of osteoporosis.
Altogether, this work demonstrates that CD18 functions critically
in the osteogenesis of BMSSCs, and thus lack of CD18 expression
in the leukocyte adhesion deficiency patientsmay predispose them
to osteoporosis.
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Osteoporosis is characterized by excessive loss of bone anddeterioration of bone tissue due to an overall imbalance
between osteoblast-mediated bone formation and osteoclast-
mediated bone resorption. Osteoblasts are derived from the
bone marrow stromal stem cells (BMSSCs) (1) and play critical
roles in the maintenance of bone mineral density (BMD) and in
the formation of a bone marrow niche microenvironment that is
essential for hematopoiesis (2, 3). When implanted s.c., the
BMSSCs are capable of forming ectopic bone and bone marrow
(4). Given their osteogenic capability, the in vitro expanded
BMSSCs have been successfully used clinically to repair frac-
tured bones (5). However, because of a lack of specific markers
for stromal stem cells, isolation and in vitro expansion of highly
purified BMSSCs in large quantity is still challenging.
Integrins are cell surface adhesion receptors and mediate
cell–cell and cell–matrix interactions. Recent studies demon-
strate essential roles of integrins, particularly the !1, !2, and !3
subfamilies, in bone formation and remodeling. The !1 integrins
are expressed on chondrocytes and are important for their
proliferation and the formation of the growth plate (6). The !3
integrins are present on osteoclasts and are required for forma-
tion of the ruffled membrane borders on the bone surface. Thus,
integrin !3 is not essential for osteoclastogenesis but, rather, is
critical to the bone-resorbing activity of the mature osteoclasts
(7). Finally, the integrin "L!2, one of the four !2 (also termed
CD18) integrins, is essential for in vitro osteoclastogenesis (8).
However, its role in osteoclast maturation in vivo remains to be
tested.
In human patients of the leukocyte adhesion deficiency type
I, the majority of the mutations occur in the CD18 subunit, which
abolishes surface expression of all four CD18 integrins ("L!2,
"M!2, "X!2, and "D!2). Because of the prominent expression of
CD18 on leukocytes, much attention in the past has been focused
on the role of CD18 in leukocyte adhesion, migration, and
immune responses. The impact of CD18 deficiency on bone
formation has not been evaluated. In this work, we report that
CD18 is expressed by BMSSCs, and CD18 deficiency abolishes
osteogenesis, resulting in reduced BMD. Mice lacking CD18
display certain features of osteoporosis, including decreased
BMD and increased trabecular bone space, suggesting that
human leukocyte adhesion deficiency type I patients also could
be predisposed to osteoporosis. Based on the differential ex-
pression pattern of CD18 on the differentiated mesenchymal
cells vs. the BMSSCs, we speculated that CD18 could be a unique
cell-sorting marker for the enrichment of human BMSSCs. We
provided a proof of principle that combining CD18 with other
stromal stem cell markers in cell sorting could significantly
enhance the isolation of BMSSCs from human bone marrow
aspirates. Altogether, our results demonstrate that CD18 plays
a critical role in the osteogenesis of the BMSSCs, thus empha-
sizing the intimate relationship between the stromal stem cells
and the hematopoietic stem cells (HSCs).
Methods
Mice. The CD18-null (CD18!/!) mice and their sex-matched
C57BL"6J littermates were obtained by breeding heterozygotes
of the CD18!/! mice (9). The CD18!/! mice have been back-
crossed by "10 generations into the C57BL"6J background.
Animals were housed in a pathogen-free facility, and all proce-
dures were performed with the approval of the Institutional
Animal Care and Use Committee of the American Red Cross
and the National Institute of Dental and Craniofacial Research.
BMSSC Culture and in Vivo Bone Formation Assay. Preparation and
expansion of the BMSSCs was done based on methods described
in refs. 4 and 10 (detailed methods are provided as Supporting
Materials and Methods, which is published as supporting infor-
mation on the PNAS web site). Briefly, mouse bone marrow
mononuclear cells with the nonadherent cells removed were
cultured on 10-cm culture dishes by using the irradiated guinea
pig bone marrow as feeder cells. Human BMSSCs were prepared
from human bone marrow aspirates of healthy adult volunteers,
by using the above procedure but in the absence of the feeder
cells. For in vivo bone formation, the expanded BMSSCs were
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mixed with hydroxyapatite"tricalcium phosphate ceramic pow-
der. The mixture was implanted s.c. into the dorsal surface of
nude mice, and the implants were harvested at 7 weeks after
implantation. Histological analysis and quantification of bone
formation in the harvested implants were performed as de-
scribed in ref. 11.
Enrichment of BMSSCs by FACS. Detailed procedures for enrich-
ment of the BMSSC population by cell sorting are described in
ref. 12 and also are provided in Supporting Materials and
Methods. Brief ly, bone marrow mononuclear cells were stained
with mAb STRO-l (IgM), anti-IgM-biotin, streptavidin-
microbeads, and finally streptavidin-FITC. The STRO-1#
population were enriched by using a Mini MACS magnetic
column (Miltenyi Biotec, Auburn, CA) and then stained
sequentially with mAb 6.7 (against human CD18; IgG) and
PE-conjugated anti-mouse IgG (both from Pharmingen) at
4°C. The STRO-1bright"CD18# BMSSC population was en-
riched by dual-color cell sorting by using a FACSkfLus f low
cytometer (Becton Dickinson). The sorted BMSSCs, either
STRO-1bright"CD18# or STRO-1bright"CD18!, were plated on
the culture dishes and subjected to colony-forming unit fibro-
blast (CFU-F) assays based on the method described in ref. 13.
Colonies were counted 12 days after cultivation.
In Vitro Differentiation Potentials of BMSSCs. Osteogenic differen-
tiation of BMSSCs was induced in the presence of 100 #M
L-ascorbate-2-phosphate, 3 mM inorganic phosphate, and 10 nM
dexamethasone. Mineral deposits were identified by Alizarin
Red S staining after 3 weeks of cultivation (8). Adipogenesis was
induced in "-MEM supplemented with 15% FBS, 100 #M
L-ascorbate-2-phosphate, 0.5 mM isobutyl-methylxanthine, 0.5
#M hydrocortisone, 60 #M indomethacin, and 10 #g"ml recom-
binant human insulin. Oil Red O staining was used to identify
lipid-laden fat cells after 2 weeks of cultivation, as described in
ref. 9. Chondrogenic differentiation was assessed by Alcian blue
staining of the cartilage matrix deposition in aggregate cultures
treated with 100 #M L-ascorbate-2-phosphate, 2 mM sodium
pyruvate, 1% insulin"transferring"selenous acid mixture (BD
Biosciences), 100 nM dexamethasone, and 10 ng"ml TGF as
described in ref. 10.
Analysis of Bone Phenotypes. Radiographs of mouse femurs were
taken by Faxitron X-ray (Wheeling, IL). Quantitative analysis
for BMD was based on dual x-ray absorptiometry by using a
Piximus (GE Lunar, Madison, WI). Distal femoral metaphyses
were analyzed by microcomputed tomography (#CT-20; Scanco
Medical, Bassersdorf, Switzerland). To analyze the whole skel-
eton, 1-week-old mice were dissected to remove skin, muscle,
and fat and kept in acetone to remove further fat for 3 days. They
then were stained with 0.09% alizarin red S and 0.05% Alcian
blue in a solution containing ethanol, glacial acetic acid, and
water (67:5:28) for 48 h at 37°C. After staining, mice were
transferred to 1% potassium hydroxide until the skeleton was
clearly visible. Mice were preserved in 100% glycerol with
gradual increase in concentration.
Osteoclast Activity. The tartrate-resistant acid phosphate staining
was performed as described in ref. 14. Serum concentration of
C-terminal telopeptides of type 1 collagen in mice was measured
by using the Ratlap ELISA kit (Osteometer BioTech A"S,
Herlev, Denmark).
Retroviral-Mediated CD18 Expression in BMSSCs. The CD18 cDNA
was subcloned into the retroviral expression vector MGIN (15),
and viral supernatants (6 $ 106 cfu"ml) were prepared by using
the packaging cell line GP#E-86 (16). CD18 expression on
BMSSCs was achieved by viral infection (50–70% efficiency)
using our published methods (17) and was verified by FACS
analysis using mAb C71"16 and by immunoblot using a poly-
clonal Ab against the cytoplasmic tail of CD18.
Analytical Methods. FACS analysis, immunoblot, cell adhesion
assay, CFU-F assay, and BrdUrd labeling were conducted based
on our published procedures (refs. 11 and 17; detailed methods
also are provided in Supporting Materials and Methods).
Results
CD18 Is Expressed on BMSSCs and Can Be Used Efficiently as a Cell
Surface Marker for Isolation of BMSSCs by Cell Sorting. CD18 is
primarily expressed on cells of the hematopoietic origin (18). To
examine whether CD18 is also expressed on BMSSCs, we
generated murine BMSSCs from the wild-type (WT) mice under
established culture conditions (4, 10) (a detailed description of
the culture method can be found in Supporting Materials and
Methods). Dual-color FACS analyses of the BMSSCs, which
were derived directly from bone marrow without cell passage
(i.e., passage 0), showed that amajor cell population (%65%) was
double positive for CD18 and Sca-1 [a stromal stem cell marker
(19)] (Fig. 1Aa). Expression of CD18 was not due to contami-
nating macrophages because the CD18# cells were negative for
CD14, a commonly used macrophage marker (Fig. 1Ab). In
addition, we found that the CD18# BMSSCs did not express
Fig. 1. CD18 is expressed by the BMSSCs. (A) Dual-color FACS analyses of the
P0 murine BMSSCs, using mAbs specific for CD18, CD14, Sca-1, and CD34. (d)
Isotype-matched IgGs were used as controls. (b) Lack of contaminating mac-
rophages within P0 BMSSCs is demonstrated by the negative CD14 staining of
CD18# BMSSCs. CD18 is coexpressed with Sca-1 (a) but not CD34 (c). The
percentages of each population were shown in the quadrants. (B) Analysis of
CD18 expression in murine and human BMSSCs by immunoblot, using a
polyclonal Ab specific for CD18 cytoplasmic domain. CD18 expression was
decreased in bothmurine and human BMSSCs upon consecutive cell passages.
Equal protein loading was confirmed by reprobing with mAbs specific for
!-actin or "-actinin. The data shown are representative of two independent
experiments.
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CD34 (a HSC marker) (Fig. 1Ac). As further support, immu-
noblot analyses showed that both murine and human BMSSCs
expressed CD18, and in both cases, the expression level de-
creased upon consecutive cell passages (Fig. 1B). Given the
presence of CD18 on the BMSSCs, we tested the possibility of
using CD18 as a selection marker for these stem cells, because
identification of additional stem cell markers would be beneficial
to stem cell purification and stem cell-based therapies (20). As
proof of principle, we sorted BMSSCs from human bone marrow
aspirates based on dual expression of CD18 (mAb 6.7) and the
stromal stem cell marker, STRO-1 (12, 20–22) (Fig. 2A) and then
determined the number of stromal stem"progenitor cells within
the sorted cells by CFU-F assays (Fig. 2B). The results showed
that dual-color FACS isolation of the bonemarrowmononuclear
cells coexpressing integrin CD18 and STRO-1 (Fig. 2A; R2,
CD18#STRO-1bright) resulted in a 15-fold enhancement in the
total number of BMSSC colonies (Fig. 2B) when compared with
the CD18-negative population (R3, CD18!STRO-1bright). Phe-
notypical characterization of the CD18#STRO-1bright cells
showed that they expressed CD44, CD166, CD106, CD90,
CD105, and CD146, but not CD45 (a leukocyte marker), CD14
(a macrophage marker), or CD34 (Fig. 2C), which is consistent
with the dual-color FACS results for murine BMSSCs (Fig. 1A).
When cultured in specific differentiation-inducing conditions,
the CD18#STRO-1bright cells were capable of differentiating into
adipocytes (Fig. 2Da) osteoblasts (Fig. 2Db), and chondrocytes
(Fig. 2Dc), thus confirming their differentiation potentials.
Together, the above results demonstrate that integrin CD18 is
expressed on BMSSCs and suggested that it could be used
efficiently as a marker for cell sorting of the BMSSC population.
Mice Lacking CD18 Have Normal Skeletal Development but Exhibit
Features of Osteoporosis. To determine whether CD18 played a
role in the function of BMSSCs, we examined bone phenotypes
of the CD18!/! [knockout (KO)] mice. Compared with theirWT
sex-matched littermates, genetic inactivation of CD18 led to a
significant (P& 0.05) decrease in BMD of the femurs taken from
both 5-week-old (n ' 3) and 15-week-old (n ' 4) mice, as
assessed by Faxitron (Fig. 3A) and dual x-ray absorptiometry
(Fig. 3B). The bone defects did not exacerbate with age between
5 and 15 weeks (data not shown), suggesting that the reduced
BMD in the deficient animals was less likely due to chronic
inflammation. Histological analysis of the femurs demonstrated
that CD18!/! mice had decreased trabecular bones in the distal
metaphysis (Fig. 3C), and microcomputed tomography analysis
of the distal femur metaphysis indicated that bone volume,
trabecular bone number, and trabecular bone thickness were
Fig. 2. Multipotent differentiation capability of the STRO-1bright"CD18#
BMSSCs. (A and B) Enrichment of the STRO-1bright"CD18# BMSSC population
by cell sorting. Fresh human bone marrow mononuclear cells were subjected
to cell sortingusingbothSTRO-1andCD18as specificmarkers. Twodistinct cell
populations (R2, STRO-1bright"CD18#; and R3, STRO-1bright"CD18!) were col-
lected (A) and subjected to CFU-F assays (B). The STRO-1bright"CD18# cells
formedmuchhigher number of colonies than the STRO-1bright"CD18! cells. (C)
Phenotypic characterization of the sorted human STRO-1bright"CD18# BMSSCs
was performed by FACS analysis using different lineage-specific mAbs (filled
in red). Their corresponding isotype-matched nonimmune IgGs were used
as controls (bold line). The numbers given indicate the percentages of
the positive cell population. Lack of macrophage contamination of the
STRO-1bright"CD18# BMSSCs was demonstrated by the negative staining of
either CD14 or CD45. (D) Differentiation potential of the STRO-1bright"CD18#
BMSSCs. The sorted STRO-1bright"CD18# cells were cultured in vitro under
adipogenic induction condition for 2 weeks (a), osteogenic induction condi-
tion for 3weeks (b), and chondrogenic induction condition for 3weeks (c). Oil
RedO staining demonstrates the generation of lipid-laden adipocytes (yellow
arrows) (a); Alizarin Red S staining showsmineral deposits (blue arrows)made
by osteogenic cells (b); and Alcian blue staining of the cartilage matrix
deposition (green arrows) demonstrates the chondrogenic differentiation in
aggregate cultures (c). Thedata shownare representativeof two independent
experiments. (Magnification: a and b, $400; c, $64.)
Fig. 3. Phenotypic comparisons between CD18!/! mice and their WT sex-
matched littermates. (A) Faxitron analysis demonstrated a decreased bone
density in the femurs of 5-week-old CD18!/! mice (KO, Right) as compared
with theirWTcounterparts (Left). (B) Dual x-ray absorptiometry analysis of the
femurs from 15-week-old mice showed a statistically significant difference in
BMDbetweenWT (left bar) and CD18!/! (right bar)mice (P' 0.025,n' 4). (C)
Hematoxylin"eosin staining on the metaphysis area of the femurs showed
diminished trabecular bone structure in CD18!/! (Right) mice as compared
with WTmice (Left). (Magnification:$400.) (D) Representative images of the
distal femur metaphysis on microcomputed tomography analysis revealed
decreased bone volume, trabecular bone number, trabecular bone thickness,
and an increased trabecular bone space. (E) Alizarin red and Alcian blue
double skeletal staining for bone (red) and cartilage (blue) of 1-week-old
mice. KO, CD18!/!.
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diminished, and trabecular bone space was increased in CD18!/!
mice (Fig. 3D and Table 1). No significant defect in skeletal
development was observed in CD18!/! mice as compared with
their WT control mice littermates (1-week-old) (Fig. 3E).
Deficiency in CD18 Does Not Affect Overall Osteoclastic Activity.
Proper BMD is maintained through a balance between oste-
oclast-mediated bone resorption and osteoblast-mediated bone
formation (23), both of which require engagement of the integrin
receptors. It is reported that chondrocyte-specific inactivation of
integrin !1 compromised bone development due to defective
formation of the growth plate (6), and inactivation of integrin !3
results in osteopetrosis due to defective bone absorbing activity
of mature osteoclasts (7). Given that genetic deletion of "L!2,
whose expression is also defective in the CD18!/! mice, affects
osteoclastogenesis (8), we anticipated that the osteoclastic ac-
tivity in the CD18!/! mice should be decreased. To test this
hypothesis, we carried out quantitative measurement of in vivo
osteoclastic activity, based on the serum concentration of the
C-terminal telopeptides of type 1 collagen, a commonly used
marker for bone resorption (24). No significant difference
between the deficient and WT mice was observed (Fig. 4A). To
further evaluate the effect of CD18 deficiency on osteoclast
formation, the total number of mature osteoclasts in the long
bones of CD18!/! mice was quantified by tartrate-resistant acid
phosphate staining (Fig. 4B; red), and no difference was found
between the deficient and WT mice.
CD18 Is Important for BMSSC Differentiation but Not for Proliferation.
The above data suggest that osteoclast-mediated bone resorption
is less likely responsible for the decreased bone formation in the
CD18!/! mice. Therefore, we hypothesized that genetic inacti-
vation of CD18 impaired osteogenic activity of the BMSSCs,
leading to the observed decreased bone formation. To test this
hypothesis, we performed in vitro mineralization induction as-
says on both WT and CD18!/! BMSSCs and found that min-
eralization by the CD18!/!BMSSCs was significantly lower (P&
0.01) than that by WT cells (Fig. 5A). In addition, CD18!/!
BMSSCs adhered poorly to tissue culture dishes in comparison
with their WT counterparts (Fig. 5B). Interestingly, the deficient
BMSSCs proliferated better than the WT cells (P ' 0.01) based
on BrdUrd incorporation assays (Fig. 5C), and the bone marrow
from CD18!/! mice contained higher numbers of single colony-
derived BMSSCs (CFU-F) (P & 0.01) than that from WT mice
(Fig. 5D).
Cbfa1 (Runx2"AML3"PEBP2"C) is a master regulatory gene
in osteogenesis (25), and its biological effects are regulated by
TGF-! through the Smad pathway (26, 27). We found that Cbfa1
expression in CD18!/! BMSSCs was decreased when compared
with that of WT BMSSCs (Fig. 6A Upper). In addition, an
increased response of Smad2 phosphorylation to TGF-! treat-
ment was observed in CD18!/! BMSSCs (Fig. 6A Lower).
Expression of Full-Length CD18 in BMSSCs Promotes Osteogenesis.To
further confirm the critical role of CD18 in BMSSCs-mediated
Table 1. Microcomputed tomography analysis of distal femoral
metaphyses from 5-week-old mice
Indices WT KO P value
BV"TV, % 17.8 8.52 0.0041
Tb.N, mm!1 5.78 3.41 0.012
Tb.Th, #m!1 31 25 0.022
Tb.Sp., #m!1 151 348 0.035
Scanning regions were confined to secondary spongiosa and were %0.30
mm in thickness. Guided by the 2D images, a region of interest was manually
drawn near the endocortical surface. Trabecular bone morphometric indices,
including bone volume relative to tissue volume (BV"TV), trabecular number
(Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp), were
assessed based on the reconstructed 3D images. WT, n ' 6 mice; KO, n ' 7
mice.
Fig. 4. CD18!/! mice exhibit normal osteoclastic activity. (A) In vivo oste-
oclastic activity was determined based on the serum concentration of C-
terminal telopeptides of type 1 collagen. No significant difference in the total
in vivo osteoclastic activity was observed between WT and the deficient mice
(P' 0.68, n' 3 mice). (B) The number of mature osteoclasts in the femurs of
the WT and CD18!/! mice was determined by tartrate-resistant acid phos-
phate staining. Similar numbers of osteoclasts were observed in WT and
CD18!/! mice (P ' 0.13, n ' 4 mice). (Magnification: $200.)
Fig. 5. CD18 deficiency compromises BMSSC differentiation but not prolif-
eration. (A) In vitromineralization induction of BMSSCs.Mineralization of the
CD18!/! BMSSCs, determined by Alizarin red S staining (magnification:$10),
was significantly lower than that of WT cells (P ' 0.00003, n ' 3 mice). The
total mineralized area by WT cells was assigned to 100%. (B) Cell adhesion.
BMSSCs were allowed to adhere for 3 h at 37°C. After washing, the adherent
cells were counted manually based on 10 randomly picked view fields and
expressed as a percentage ofWT cell adhesion. The CD18!/! BMSSCs adhered
poorly comparedwith theWTcells (P'0.03,n'4). (C) ProliferationofBMSSCs
was evaluated by BrdUrd incorporation, and the percentage of BrdUrd# cells
was determined manually by counting 10 representative fields. CD18!/!
BMSSCs proliferate better than the WT controls (P ' 0.01, n ' 3 mice). (D)
CFU-F assay. The number of BMSSC colonies obtained from 106 bone marrow
cells was significantly increased for the CD18!/!mice (P' 0.0064, n' 6mice).
(Magnification: $10.)
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osteogenesis, and to exclude the possibility that CD18 contrib-
utes indirectly to osteogenesis through its function in hemato-
poetic cells, we conducted function–rescue experiments by ex-
pressing either full-length or cytoplasmic domain-truncated
CD18, CD18 (CT!), in CD18!/! BMSSCs. Similar to WT
BMSSCs, no macrophage contamination was detected in the P0
CD18!/! BMSSCs by FACS analysis (data not shown). To
express recombinant CD18, the CD18!/!BMSSCs were infected
with retroviruses carrying either full-length CD18 or mutant
CD18 (CT!). Expression of recombinant CD18 on BMSSCs was
confirmed 6 days after infection by immunoblot, using a poly-
clonal Ab against the cytoplasmic tail of CD18 (Fig. 6B). The
osteogenic capability of WT BMSSCs, CD18!/! BMSSCs and
the two different CD18-expressing CD18!/! BMSSCs was eval-
uated by using an in vivo model of ectopic bone formation (11).
Consistent with the decreased osteogenic activity of the
CD18!/! BMSSCs in vitro (Fig. 5A), we found that the CD18!/!
BMSSCs failed to support bone formation in vivo (Fig. 6 C and
D; WT vs. KO, P' 0.016), which was restored by the expression
of full-length CD18 in the CD18!/! BMSSCs (KO vs. CD18, P'
0.0001). Surprisingly, the BMSSCs expressing CD18 constitu-
tively by using the retroviral promoter exhibited significantly
higher in vivo osteogenic activity (%3-fold over WT BMSSCs;
WT vs. CD18, P' 0.0047), indicating that prolonged expression
of CD18 on BMSSCs enhances osteogenesis. In contrast, ex-
pression of a cytoplasmic domain-truncated CD18 failed to
rescue the defective phenotype of bone formation [KO vs. CD18
(CT!), P ' 0.39], suggesting that the cytoplasmic domain of
CD18, which is required for integrin ‘‘outside-in’’ signaling, is
required for the osteogenic differentiation of the BMSSCs.
Discussion
The stromal stem cells are potentially involved in the replenish-
ment of a wide range of cell types through an adult life, including
osteoblasts, chondrocytes, adipocytes, neural cells, and marrow
stromal cells. Thus, BMSSCs represent an easily accessible and
renewable source of stem cells for tissue engineering to repair
damaged tissues (1). In addition, osteoblasts derived from
BMSSCs are critical to the maintenance of the niche microen-
vironment for hematopoiesis (2, 3). However, because of the
heterogeneity of BMSSCs and lack of specific surface markers
for them, our understanding toward this type of stem cells is still
limited. In this work, we identified a unique surface marker,
CD18, for the BMSSCs and successfully used this previously
undescribed stromal stem cell marker to enrich the BMSSCs
population by cell sorting. Most importantly, we demonstrate
that CD18 plays a critical role in osteogenesis of the BMSSCs,
and mice lacking CD18 exhibit certain features of osteoporosis,
including decreased BMD, reduced trabecular bone number,
decreased trabecular bone thickness, and increased trabecular
bone space.
It is surprising that CD18, a protein known to exist only on
hematopoietic cell surface, is also expressed by the BMSSCs.
Especially, we found that CD18 is highly expressed on the
BMSSCs of the early passages after their purification from bone
marrow. Given such a distinct pattern of expression, CD18 could
be a useful surface marker for cell sorting to enrich the stromal
stem cell population, because most of the other surface markers
for stromal stem cells, including STRO-1, CD106"VCAM-1,
CD146"MUC-18, HOP-26, CD49A"integrin !1, and SB-10"
CD166 (20, 22, 28), are expressed both on progenitor and on
differentiated mesenchymal cells. As proof of principle, we
isolated BMSSCs from human bone marrow aspirates by cell
sorting using both CD18 and STRO-1, a cell marker commonly
used for stromal stem cells (12). The number of stromal stem
cells obtained in the CD18#STRO-1bright population was 15-fold
higher than that of the CD18!STRO-1bright population, suggest-
ing that only the CD18-expressing cells in the STRO-1bright
population are capable of self-renewal. Thus, this previously
unidentified stromal stem marker should be helpful in the
enrichment and in vitro expansion of the BMSSCs for therapeutic
applications. Furthermore, because prolonged expression of
CD18 on BMSSCs results in significantly enhancement of os-
teogenesis and bone formation (Fig. 6D), we anticipate that
retroviral mediated expression of CD18 on BMSSCs could be
beneficial to tissue engineering of bone and bone marrow.
In addition to CD18, another known HSC marker, Sca-1, also
is expressed on stromal stem cells (19). Deficiency of Sca-1 leads
to defects in HSC renewal (29) and mesenchymal stem cell
renewal (30). As a result, Sca-1-deficient mice exhibit signs of
osteoporosis, caused by both reduced bone formation and
decreased bone resorption (30). Unlike Sca-1, we found that
CD18 deficiency affected the differentiation, but not prolifera-
tion, of BMSSCs (Fig. 5). Whether CD18 deficiency also affects
the differentiation and renewal of HSC is currently unclear and
needs further investigation. It has been reported that CD18
Fig. 6. Defective osteogenic capability of the CD18!/! BMSSCs. (A) Cbfa1
expression and Smad2 phosphorylation by immunoblot. Compared with WT
cells, the CD18!/! BMSSCs exhibited decreased Cbfa1 expression (Upper) and
enhanced response toward TGF-! stimulation, as indicated by Smad2 phos-
phorylation (Lower). Equal protein loadingwas verified by reprobingwith an
"-actinin-specific mAb. The data shown are representative of three indepen-
dent experiments. (B) Retroviral mediated expression of recombinant CD18.
The CD18!/! BMSSCs were infected with retroviral supernatants encoding
either full-length CD18 or the cytoplasmic tail-truncated CD18 (CT!) for 6
days, and expression of recombinant CD18 was determined by immunoblot,
using an anti-CD18 cytoplasmic tail Ab, which does not react well with CD18
(CT!). Noninfected WT and CD18!/! BMSSCs were included as controls, and
protein loading was shown by reprobing for "-actinin. (C) Bone formation
in vivo. WT, CD18!/!, as well as the retroviral-infected CD18!/! BMSSCs with
either CD18 or CD18 (CT!) were mixed with hydroxyapatite"tricalcium phos-
phate and then implanted s.c. in nude mice. The BMSSC-mediated bone
formation was analyzed 7 weeks after implantation by hematoxylin"eosin
staining. B, newly formed bone; HA, hydroxyapatite"tricalcium phosphate;
CT, connective tissues. (Magnification: $200.) (D) Restoration of the osteo-
genic capability of the CD18!/! BMSSCs. The amount of bone formation in C
was quantified by using the software NIH IMAGE (http:""rsb.info.nih.gov"nih-
image) based on five representative areas and was expressed as a percentage
of bone formation by WT BMSSCs. Bone formation by CD18!/! BMSSCs was
significantly decreased comparedwith theWTBMSSCs (P' 0.008,n' 4mice).
The defective osteogenesis of CD18!/! BMSSCs was rescued by expression of
CD18 (P ' 0.0001, n ' 4 mice) but not CD18 (CT!) (P ' 0.39, n ' 4 mice).
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deficiency causes severe leukocytosis (9), which may potentially
lead to increased numbers of osteoclast precursor cells in the
deficient mice. However, the defective expression of "L!2 (one
of the four CD18 integrins) in CD18!/! mice also decreases
osteoclastogenesis (8). As a result, the overall osteoclastic ac-
tivity in the CD18!/!mice remains unchanged (Fig. 4). Another
interesting question that remains to be answered is whether the
decreased differentiation of CD18!/! BMSSCs affects the niche
microenvironment and therefore indirectly influences hemato-
poiesis. It is known that the CD18!/! HSCs can be easily
mobilized into the blood circulation, due in part to the decreased
HSC adhesion to bone marrow stroma (31). Our work suggests
an additional possibility that CD18 deficiency in mice may affect
the bone marrow stroma, thus diminishing the retention of HSCs
within the bone marrow. Further studies will be required to test
these hypotheses.
In conclusion, our work demonstrates that CD18 is a previ-
ously undescribed surface marker for both human and mouse
BMSSCs.We provided a proof of principle that combining CD18
with other independent stromal stem cell markers (e.g., STRO-1,
CD106"VCAM-1, and CD146"MUC-18) (20, 22) in cell sorting
could significantly enrich the BMSSC population from unfrac-
tionated bone marrow aspirates, which could facilitate the use of
purified and in vitro expanded BMSSCs for clinical application.
Given the osteoporotic phenotype of the CD18!/! mice, our
work suggests a strong possibility that patients with the severe
form of leukocyte adhesion deficiency type I, including those
with restored HSC functions by gene therapy, could be predis-
posed to bone defects and the development of osteoporosis.
Thus, it would be necessary to include reconstitution of CD18
expression on both HSCs and BMSSCs for therapeutic treat-
ments of the leukocyte adhesion deficiency type I patients in the
future.
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